STARTVerso™ 4 is an open-label, sponsor blinded, Phase 3 study assessing the efficacy and safety of Boehringer Ingelheim's investigational oral protease inhibitor faldaprevir in combination with PegIFN/RBV. The study includes 308 individuals co-infected with HCV and HIV who were treatment-naive (TN) or had relapsed after previous HCV therapy with PegIFN/RBV, and were either HIV treatment-naive or being treated with ART. The trial includes patients with cirrhosis (17% had F4 cirrhosis or Fibroscan >13 kPa).

Group 1: 12 or 24 weeks of faldaprevir 240mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV

Group 2: 24 weeks of faldaprevir 120mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV

About Boehringer Ingelheim in Hepatitis C Virus (HCV)

In partnership with the scientific community, our clinical trial program, HCVerso™, is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. The ongoing multi-study Phase 3 STARTVerso™ trial program, evaluating faldaprevir combined with PegIFN/RBV in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV, is near clinical completion. BI 207127 is an investigational NS5B non-nucleoside polymerase in'/>"/>

(Date:3/31/2015)... HOUSTON , March 31, 2015 ... at the American Association of Orthodontics 2015 Annual ... leading orthodontists present scientific lectures on AcceleDent ® ... the leader in accelerated orthodontics, AcceleDent is a ... orthodontic treatment by as much as 50 percent ...

(Date:3/31/2015)... ALTO, Calif. , March 31, 2015 Frequentz ... visibility, has released a white paper to help the ... the 2013 Drug Supply Chain Security Act (DSCSA). The ... various stages of the GS1 EPCIS Standard(s) ... detailed outlook on the product tracing requirements that need ...

(Date:3/31/2015)... 31, 2015 Mark Farrah Associates (MFA), ... (MA) plans in their recent analysis brief. According ... enrolled in Medicare Advantage plans as of March ... members year-over-year. 54.3 million people are eligible for ... Medicaid Services (CMS), with an unpenetrated market of ...

... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... will be held on Thursday, November 3, 2011 at ... quarter ended September 30, 2011 and a business outlook ...

... Nov. 1, 2011 Genomic Health, Inc. (Nasdaq: GHDX ... ended September 30, 2011. Total revenue increased to $52.1 ... in the third quarter of 2010. Product revenue was $51.7 million ... compared with $45.8 million in the third quarter of 2010. ...

(Date:3/31/2015)... NORWOOD, NJ (PRWEB) March 31, 2015 ... College of Health Care Administrators (ACHCA) elected two ... of short- and long-term care in New Jersey, ... annual election of new officers. Robert Reyes, administrator ... Brook, was elected president, and Yael Herman, administrator ...

(Date:3/31/2015)... (PRWEB) March 31, 2015 Tickets are ... show and Denver tradition since 1973. The 2015 Spring ... of Showtime on Ice. On April 24 in partnership ... event and opening night tribute to the Pat Bowlen ... A portion of the opening event proceeds will go ...

(Date:3/31/2015)... 2015 Rising rates of anterior cruciate ... and surgeons to better analyze and investigate ways to ... repair. A recent study published online in ... of 1,016 young, very active patients to compare ACL ... “This is the first review to examine young, active ...

... and its subsidiary, Fisher-Price, have been fined $2.3 million for ... to the Consumer Product Safety Commission, the toymaker violated a ... having intentionally violated the ban. The fine is a result ... 2007, when the companies recalled toys including Elmo, Barbie, Big ...

... China, June 19 /PRNewswire-Asia/ -- On June 3, 2009, the ... that as of,June 1, 2009, the tax rebate rate for ... two (2) percent. As a leading exporter of,medical dressing products ... Medical", or the "Company") will greatly,benefit from this policy to ...

... 19 Kensey Nash Corporation (Nasdaq: KNSY ... and technologies for a wide range of medical procedures, ... stockholders, rights plan. The rights plan is designed to ... takeover practices or takeover bids and to prevent an ...

... 500 Company,s Innovative Vision for ,Community Care, , , ... ), a leading provider of kidney care services for those ... Community Care Report to share the company,s vision of corporate ... DaVita,s efforts since it began in 1999. DaVita(R) teammates ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...